Bayer is leaving. SEVA is staying.
Bayer has end-of-lifed four contrast injector product lines across angiography, CT, and MR. Two are already past their cutoff. Two more follow on 12/31/2028. SEVA supplies compatible disposables for the equipment your department already owns, with no forced capital event and no bundling.
Four letters. One pattern.
The strongest evidence of Bayer's end-of-life strategy is Bayer's own communications to customers. SEVA quotes these letters directly, with full attribution and document references.
The pattern is consistent across all four: Bayer announces end of life, names the upgrade product, and directs the customer to a Bayer sales representative. The upgrade products carry new proprietary disposables and new capital requirements. SEVA's offer is the alternative Bayer does not name.
"After December 31, 2025, Bayer will no longer offer service, including preventative maintenance, equipment calibration, replacement parts and technical support, or consumables for the installed base of the MEDRAD® Mark V ProVis systems in the US."
"After December 31, 2025, Bayer will no longer offer service, including preventative maintenance, equipment calibration, replacement parts and technical support, or consumables for the installed base of the MEDRAD® Spectris Solaris systems in the US. This notification does not apply to the MEDRAD® Spectris Solaris EP MR Injection Systems."
"After December 31, 2028, Bayer will no longer offer service, including preventative maintenance, equipment calibration, replacement parts and technical support, or consumables for the installed base of the MEDRAD® Stellant Classic CT Injection Systems in the US."
Spectris Solaris EP MR, including the EP Mobile variant, follows the same Bayer end-of-life template with a 12/31/2028 cutoff. Service, parts, and consumables discontinued after that date. Bayer's recommended upgrade is MEDRAD® MRXperion.
A four-stage squeeze. With a way out.
Bayer's EOL letters are not isolated product lifecycle events. They follow a deliberate four-stage sequence, each stage tightening a department's available options. Understanding the sequence helps radiology administrators plan ahead.
Coverage Renewal
The final opportunity to purchase full-service support coverage for affected platforms. This window has already closed for all four EOL platforms.
Limited Service
Reduced service options. Parts availability declines. Bayer applies increasing pressure to begin the upgrade conversation. This is the current window for Stellant and Spectris EP facilities.
Forced Upgrade
Migrate to Stellant FLEX or MRXperion. New proprietary disposables. New capital outlay per injector head. Replacement injectors run $20,000 to $50,000 per unit. No clinical differentiation from existing equipment.
End of Life
No Bayer service. No parts. No consumables. No support. Equipment becomes unsupported without an independent disposables supplier. SEVA supplies past this date.
Keep your equipment. Keep imaging.
SEVA's offer to a Stellant-, Spectris Solaris-, or ProVis-equipped facility is the inverse of Bayer's. No forced capital event. No new proprietary lock-in. No clinical disruption.
-
Keep your existing equipment operational SEVA-supplied syringes and disposables for Stellant Classic, Spectris Solaris MR, Spectris Solaris EP MR, and Mark V ProVis. Same injector. Same workflow. Same imaging performance.
-
No capital outlay The injector your department already owns continues to function. No $20,000 to $50,000 per-head replacement cost. No multi-room capital event. No budget cycle disruption.
-
No proprietary lock-in SEVA's products are not bundled with contrast media and not tied to a closed platform. Your existing contrast relationships are unaffected. Pricing is negotiated directly.
-
No clinical disruption Same load procedure. Same technologist training. Same imaging protocol. SEVA syringes are validated for drop-in compatibility with the existing injector head. Nothing changes in the suite.
-
Predictable, direct pricing Transparent per-unit and per-study pricing. No bundling. No contrast media tie-in. GPO access via HPG for member facilities. Direct contracting for all others.
Your platform. Your guide.
Four injector-specific transition guides, one for each Bayer EOL platform. Present-tense for platforms already past their cutoff. Forward-looking for platforms approaching 2028. Each guide covers SEVA's supply commitment, compatibility details, and the evaluation process.
Mark V ProVis Transition Guide
Written in the present tense because the EOL date has passed. Facilities operating Mark V ProVis equipment are actively sourcing alternative disposables now. SEVA is the answer.
- OEM EOL12/31/2025 (past)
- Bayer UpgradeMEDRAD® Mark 7 Arterion
- SEVA ProductComplete angio injection kits
- Supply StatusContinuing
Spectris Solaris MR Transition Guide
The original Spectris Solaris MR (not the EP variant) reached end of life 12/31/2025. Facilities still operating this platform need a disposables source. SEVA supplies continuously.
- OEM EOL12/31/2025 (past)
- Bayer UpgradeMEDRAD® MRXperion
- SEVA ProductMR contrast syringes
- Supply StatusContinuing
Stellant Classic CT Transition Guide
Facilities on Stellant Classic have until 12/31/2028 before Bayer ends service and consumables. The time to evaluate SEVA is now, ahead of the 2027 to 2028 surge in competing demand for alternatives.
- OEM EOL12/31/2028
- Bayer UpgradeStellant FLEX + Certegra®
- SEVA ProductCT contrast syringes
- Supply StatusContinuing past 2028
Spectris Solaris EP MR Transition Guide
The Spectris Solaris EP MR (including the EP Mobile variant) follows the same 12/31/2028 Bayer cutoff as Stellant Classic. This is a separate platform and separate EOL from the original Spectris Solaris MR.
- OEM EOL12/31/2028 (incl. EP Mobile)
- Bayer UpgradeMEDRAD® MRXperion
- SEVA ProductMR contrast syringes
- Supply StatusContinuing past 2028
Everything in one place.
Downloadable guides, evaluation tools, and reference materials for every stage of the EOL transition and SEVA evaluation process. All resources available by request.
Your Bayer EOL date is set. SEVA's supply is not.
Request a transition guide for your platform, a sample evaluation kit, or a conversation with SEVA's commercial team. The earlier your facility evaluates, the more flexibility you have before the 2028 deadline.
Bayer is leaving. SEVA is staying.
Bayer has end-of-lifed four contrast injector product lines across angiography, CT, and MR. Two are already past their cutoff. Two more follow on 12/31/2028. SEVA supplies compatible disposables for the equipment your department already owns, with no forced capital event and no bundling.
Four letters. One pattern.
The strongest evidence of Bayer's end-of-life strategy is Bayer's own communications to customers. SEVA quotes these letters directly, with full attribution and document references.
The pattern is consistent across all four: Bayer announces end of life, names the upgrade product, and directs the customer to a Bayer sales representative. The upgrade products carry new proprietary disposables and new capital requirements. SEVA's offer is the alternative Bayer does not name.
"After December 31, 2025, Bayer will no longer offer service, including preventative maintenance, equipment calibration, replacement parts and technical support, or consumables for the installed base of the MEDRAD® Mark V ProVis systems in the US."
"After December 31, 2025, Bayer will no longer offer service, including preventative maintenance, equipment calibration, replacement parts and technical support, or consumables for the installed base of the MEDRAD® Spectris Solaris systems in the US. This notification does not apply to the MEDRAD® Spectris Solaris EP MR Injection Systems."
"After December 31, 2028, Bayer will no longer offer service, including preventative maintenance, equipment calibration, replacement parts and technical support, or consumables for the installed base of the MEDRAD® Stellant Classic CT Injection Systems in the US."
Spectris Solaris EP MR, including the EP Mobile variant, follows the same Bayer end-of-life template with a 12/31/2028 cutoff. Service, parts, and consumables discontinued after that date. Bayer's recommended upgrade is MEDRAD® MRXperion.
A four-stage squeeze. With a way out.
Bayer's EOL letters are not isolated product lifecycle events. They follow a deliberate four-stage sequence, each stage tightening a department's available options. Understanding the sequence helps radiology administrators plan ahead.
Coverage Renewal
The final opportunity to purchase full-service support coverage for affected platforms. This window has already closed for all four EOL platforms.
Limited Service
Reduced service options. Parts availability declines. Bayer applies increasing pressure to begin the upgrade conversation. This is the current window for Stellant and Spectris EP facilities.
Forced Upgrade
Migrate to Stellant FLEX or MRXperion. New proprietary disposables. New capital outlay per injector head. Replacement injectors run $20,000 to $50,000 per unit. No clinical differentiation from existing equipment.
End of Life
No Bayer service. No parts. No consumables. No support. Equipment becomes unsupported without an independent disposables supplier. SEVA supplies past this date.
Keep your equipment. Keep imaging.
SEVA's offer to a Stellant-, Spectris Solaris-, or ProVis-equipped facility is the inverse of Bayer's. No forced capital event. No new proprietary lock-in. No clinical disruption.
-
Keep your existing equipment operational SEVA-supplied syringes and disposables for Stellant Classic, Spectris Solaris MR, Spectris Solaris EP MR, and Mark V ProVis. Same injector. Same workflow. Same imaging performance.
-
No capital outlay The injector your department already owns continues to function. No $20,000 to $50,000 per-head replacement cost. No multi-room capital event. No budget cycle disruption.
-
No proprietary lock-in SEVA's products are not bundled with contrast media and not tied to a closed platform. Your existing contrast relationships are unaffected. Pricing is negotiated directly.
-
No clinical disruption Same load procedure. Same technologist training. Same imaging protocol. SEVA syringes are validated for drop-in compatibility with the existing injector head. Nothing changes in the suite.
-
Predictable, direct pricing Transparent per-unit and per-study pricing. No bundling. No contrast media tie-in. GPO access via HPG for member facilities. Direct contracting for all others.
Your platform. Your guide.
Four injector-specific transition guides, one for each Bayer EOL platform. Present-tense for platforms already past their cutoff. Forward-looking for platforms approaching 2028. Each guide covers SEVA's supply commitment, compatibility details, and the evaluation process.
Mark V ProVis Transition Guide
Written in the present tense because the EOL date has passed. Facilities operating Mark V ProVis equipment are actively sourcing alternative disposables now. SEVA is the answer.
- OEM EOL12/31/2025 (past)
- Bayer UpgradeMEDRAD® Mark 7 Arterion
- SEVA ProductComplete angio injection kits
- Supply StatusContinuing
Spectris Solaris MR Transition Guide
The original Spectris Solaris MR (not the EP variant) reached end of life 12/31/2025. Facilities still operating this platform need a disposables source. SEVA supplies continuously.
- OEM EOL12/31/2025 (past)
- Bayer UpgradeMEDRAD® MRXperion
- SEVA ProductMR contrast syringes
- Supply StatusContinuing
Stellant Classic CT Transition Guide
Facilities on Stellant Classic have until 12/31/2028 before Bayer ends service and consumables. The time to evaluate SEVA is now, ahead of the 2027 to 2028 surge in competing demand for alternatives.
- OEM EOL12/31/2028
- Bayer UpgradeStellant FLEX + Certegra®
- SEVA ProductCT contrast syringes
- Supply StatusContinuing past 2028
Spectris Solaris EP MR Transition Guide
The Spectris Solaris EP MR (including the EP Mobile variant) follows the same 12/31/2028 Bayer cutoff as Stellant Classic. This is a separate platform and separate EOL from the original Spectris Solaris MR.
- OEM EOL12/31/2028 (incl. EP Mobile)
- Bayer UpgradeMEDRAD® MRXperion
- SEVA ProductMR contrast syringes
- Supply StatusContinuing past 2028
Everything in one place.
Downloadable guides, evaluation tools, and reference materials for every stage of the EOL transition and SEVA evaluation process. All resources available by request.
Your Bayer EOL date is set. SEVA's supply is not.
Request a transition guide for your platform, a sample evaluation kit, or a conversation with SEVA's commercial team. The earlier your facility evaluates, the more flexibility you have before the 2028 deadline.